- Home
- Publications
- Publication Search
- Publication Details
Title
New Therapeutic Strategies in Acute Lymphocytic Leukemia
Authors
Keywords
Acute lymphoblastic leukemia, Acute lymphocytic leukemias, Therapeutic approaches, Purine nucleoside analogs, Monoclonal antibodies, Antibody drug conjugates
Journal
Current Hematologic Malignancy Reports
Volume 12, Issue 3, Pages 197-206
Publisher
Springer Nature
Online
2017-03-28
DOI
10.1007/s11899-017-0380-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia
- (2016) K Canté-Barrett et al. LEUKEMIA
- Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
- (2016) Sébastien Maury et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoclonal antibodies in acute lymphoblastic leukemia
- (2015) E. Jabbour et al. BLOOD
- Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
- (2015) J. J. M. van Dongen et al. BLOOD
- Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia
- (2015) Aradhana Awasthi et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2015) N. Daver et al. CLINICAL CANCER RESEARCH
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2
- (2015) Elizabeth A. Raetz et al. PEDIATRIC BLOOD & CANCER
- Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition
- (2014) J. Irving et al. BLOOD
- Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
- (2014) S. Suryani et al. CLINICAL CANCER RESEARCH
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
- (2014) D J DeAngelo et al. LEUKEMIA
- Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
- (2013) Loretta Sullivan-Chang et al. BIODRUGS
- Acute lymphoblastic leukaemia
- (2013) Hiroto Inaba et al. LANCET
- Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential
- (2013) L M Neri et al. LEUKEMIA
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
- (2012) N. Gokbuget et al. BLOOD
- Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
- (2012) Y. H. Messinger et al. BLOOD
- Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia
- (2012) T. Bhatla et al. BLOOD
- Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2012) S. L. Maude et al. BLOOD
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
- (2012) Stephen P. Hunger et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- Recent Research Advances in Childhood Acute Lymphoblastic Leukemia
- (2010) Ching-Hon Pui JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium
- (2010) Yoav Messinger et al. PEDIATRIC BLOOD & CANCER
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
- (2008) D. A. Thomas et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started